Genetic basis of the lipid storage disorders

Bibliography

• Beutler E, Grabowski GA: Gaucher disease. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA 3635–3668 (2001).
   Google Scholar
• Definitive chapter describing the clinical, pathologic, biochemical and molecular manifestations of Gaucher disease.
   Google Scholar
• Pastores GM, Patel MJ, Firooznia H: Bone and joint complications related to Gaucher disease. Curr. Rheumatol. Rep. 2(2), 175–180 (2000)
   Google Scholar
• Mistry PK, Sirrs S, Chan A et al.: Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol. Genet. Metab. 77(1–2), 91–98 (2002)
   Google Scholar
• Hanna R, McDonald MT, Sullivan JA, Mackey JF, Krishnamurthy V, Kishnani PS: Diagnostic and treatment challenges of neuronopathic Gaucher disease: two cases with an intermediate phenotype. J. Inherit. Metab. Dis. 27(5), 687–690 (2004)
   Google Scholar
• Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E: Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J. Pediatr. 143(2), 273–276 (2003)
   Google Scholar
• Koprivica V, Stone DL, Park JK et al.: Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am. J. Hum. Genet. 66, 1777–1786 (2000)
   Google Scholar
• Weinreb NJ, Charrow J, Andersson HC et al.: Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. 113, 112–119 (2002)
   Google Scholar
• Wilson C, Spearing R, Teague L et al.: The outcome of clinical parameters in adults with severe type 1 Gaucher disease using very low dose enzyme replacement therapy. Mol. Genet. Metab. 92, 131–136 (2007)
   Google Scholar
• Wenstrup RJ, Kacena KA, Kaplan P et al.: Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J. Bone Miner. Res. 22(1), 119–126 (2007)
   Google Scholar
• Vellodi A, Bembi B, de Villemeur TB et al.: Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease Management of neuronopathic Gaucher disease: a European consensus. J. Inherit. Metab. Dis. 24, 319–327 (2001)
   Google Scholar
• Davies EH, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A: Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J. Inherit. Metab. Dis. 30(6), 935–942 (2007)
   Google Scholar
• Desnick RJ, Ioannou YA, Eng CM: Fabry disease: -galactosidase deficiency and Schindler disease: -N-acetylgalactosaminidase deficiency. In: The Metabolic and Molecular Bases of Inherited Disease (8th Edition). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA 3733–3779 (2001).
   Google Scholar
• Definitive chapter describing the clinical, pathologic, biochemical and molecular manifestations of Fabry’s disease with more than 400 references.
   Google Scholar
• Eng CM, Fletcher J, Wilcox WR et al.: Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry J. Inherit. Metab. Dis. 30(2), 184–192 (2007)
   Google Scholar
• Nakao S, Kodama C, Takenaka T et al.: Fabry disease: detection of undiagnosed hemodialysis patients and identification of a ‘renal variant’ phenotype. Kidney Int. 64(3), 801–807 (2003)
   Google Scholar
• von Scheidt W, Eng CM, Fitzmaurice TF et al.: An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N. Engl. J.Med. 324(6), 395–399 (1991)
   Google Scholar
• Ishii S, Nakao S, Minamikawa-Tachino R et al.: Alternative splicing in the -galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am. J. Hum. Genet. 70(4), 994–1002 (2002)
   Google Scholar
• Ishii S, Nakao S, Minamikawa-Tachino R et al.: Alternative splicing in the -galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am. J. Hum. Genet. 70(4), 994–1002 (2002)
   Google Scholar
• Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M and the European FOS Investigators: Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet. 43(4), 347–352 (2006)
   Google Scholar
• Shabbeer J, Yasuda M, Luca E, Desnick RJ: Fabry disease: 45 novel mutations in the -galactosidase A gene causing the classical phenotype. Mol. Genet. Metab. 76, 23–30 (2002)
   Google Scholar
• Ashton-Prolla P, Tong B, Shabbeer J et al.: Fabry disease: twenty-two novel mutations in the -galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J. Investig. Med. 48, 227–235 (2000)
   Google Scholar
• Schaefer E, Mehta A, Gal A: Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey: Acta Paediatr. Suppl. 94(447), 87–92; discussion 79 (2005)
   Google Scholar
• Eng CM, Guffon N, Wilcox WR et al. and the International Collaborative Fabry Disease Study Group: Safety and efficacy of recombinant human -galactosidase A – replacement therapy in Fabry’s disease N. Engl. J. Med. 345(1), 9–16 (2001)
   Google Scholar
• Schiffmann R, Kopp JB et al.: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21), 2743–2749 (2001)
   Google Scholar
• Germain DP, Waldek S, Banikazemi M et al.: Sustained, long-term renal stabilization after 54 months of agalsidase therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 18(5), 1547–1557 (2007)
   Google Scholar
• Hughes DA, Elliott PM, Shah J et al.: Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase- . Heart 94(2), 153–158 (2008)
   Google Scholar
• Hoffmann B, Garcia de Lorenzo A, Mehta A et al. and the FOS European Investigators: Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J. Med. Genet. 42(3), 247–252 (2005)
   Google Scholar
• Schuchman EH, Desnick RJ: Types A and B Niemann–Pick disease. In: The Metabolic and Molecular Bases of Inherited Disease (8th Edition). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA 3589–3610 (2001).
   Google Scholar
• The most up-to-date description of the clinical, metabolic and molecular nature of Niemann–Pick disease types A and B.
   Google Scholar
• Wasserstein MP, Aron A, Brodie SE et al.: Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann–Pick disease. J. Pediatr. 149(4), 554–559 (2006)
   Google Scholar
• McGovern MM, Aron A, Brodie SE et al.: Natural history of Type A Niemann–Pick disease: possible endpoints for therapeutic trials. Neurology 66(2), 228–232 (2006)
   Google Scholar
• McGovern MM, Pohl-Worgall T, Deckelbaum RJ et al.: Lipid abnormalities in children with types A and B Niemann–Pick disease. J. Pediatr. 145(1), 77–81 (2004)
   Google Scholar
• Pavlu-Pereira H, Asfaw B, Poupctová H et al.: Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study J. Inherit. Metab. Dis. 28(2), 203–227 (2005)
   Google Scholar
• Simonaro CM, Desnick RJ, McGovern MM et al.: The demographics and distribution of Type B Niemann–Pick disease: novel mutations lead to new genotype/phenotype correlations. Am. J. Hum. Genet. 71, 1413–1419 (2002)
   Google Scholar
• Morel CF, Gassas A, Doyle J, Clarke JT: Unsuccessful treatment attempt: cord blood stem cell transplantation in a patient with Niemann–Pick disease type A. J. Inherit. Metab. Dis. 30(6), 987 (2007)
   Google Scholar
• Miranda SR, He X, Simonaro CM et al.: Infusion of recombinant human acid sphingomyelinase into Niemann–Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14(13), 1988–1995 (2000)
   Google Scholar
• Passini MA, Bu J, Fidler JA et al.: Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann–Pick mouse. Proc. Natl Acad. Sci. USA 104(22), 9505–9510 (2007)
   Google Scholar
• Wenger DA, Suzuki K, Suzuki Y, Suzuki K: Glactosylceramde lipidosis: globoid cell leukodystrophy (Krabbe disease). In: The Metabolic and Molecular Bases of Inherited Disease (8th Edition). Scriver CR, Beaudet AL, Sly WS et al. (Eds). McGraw Hill, NY, USA 3669–3694 (2001).
   Google Scholar
• Definitive chapter describing the clinical, pathologic, biochemical and molecular manifestations of Krabbe disease.
   Google Scholar
• Turazzini M, Beltramello A, Bassi R et al.: Adult onset Krabbe’s leukodystrophy: a report of 2 cases. Acta Neurol. Scand. 96(6), 413–415 (1997)
   Google Scholar
• Escolar ML, Poe MD, Provenzale JM et al.: Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. N. Engl. J. Med. 352(20), 2069–2081 (2005)
   Google Scholar
• Caggana Msaavedra C, Wenger D, Helton L, Orsini J: Newborn screening for Krabbe disease in New York State: experience from the first year. Mol. Genet. Metab. 93(2), S17 (2008)
   Google Scholar
• Duffner P, Adams D, Andriola M et al.: A consensus protocol for the clinical and neurodiagnostic evaluation of infants with positive newborn screens for Krabbe disease. Ann. Neurol. 62(Suppl. 11), S112 (2007)
   Google Scholar
• Moser HW, Raymond GV, Lu SE et al.: Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch. Neurol. 62, 1073–1080 (2005)
   Google Scholar
• Platt FM, Neises GE, Reinkensmeier G et al.: Prevention of lysosomal storage in Tay–Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428–431 (1997)
   Google Scholar
• Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek RA, Butters TD: Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos. Trans. R Soc. Lond. B Biol. Sci. 358, 947–954 (2003)
   Google Scholar
• Butters TD, Dwek RA, Platt FM: Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15(10), 43R–52R (2005)
   Google Scholar
• Cox T, Lachmann R, Hollak C et al.: Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet 355, 1481–1485 (2000)
   Google Scholar
• Capablo JL, Franco R, de Cabezón AS, Alfonso P, Pocovi M, Giraldo P: Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. Epilepsia 48, 1406–1408 (2007)
   Google Scholar
• Frustaci A, Chimenti C, Ricci R et al.: Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N. Engl. J.Med. 345, 25–32 (2001)
   Google Scholar
• Ishii S, Chang HH, Kawasaki K et al.: Mutant -galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem. J. 406(2), 285–295 (2007)
   Google Scholar
• Steet RA, Chung S, Wustman B, Powe A, Do H, Kornfeld SA: The iminosugar isofagomine increases the activity of N370S mutant acid -glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl Acad. Sci. USA 103(37), 13813–13818 (2006)
   Google Scholar
• Zheng W, Padia J, Urban DJ et al.: Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl Acad. Sci. USA 104(32), 13192–13197 (2007)
   Google Scholar
• Matsuda J, Suzuki O, Oshima A et al.: Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc. Natl Acad. Sci. USA 100(23), 15912–15917 (2003)
   Google Scholar
• Egan ME, Pearson M, Weiner SA et al.: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304, 600–602 (2004)
   Google Scholar
• Egan ME, Glockner-Pagel J, Ambrose CA et al.: Calcium-pump inhibitors induce functional surface expression of F508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. 8(5), 485–492 (2002)
   Google Scholar
• Mu TW, Fowler DM, Kelly JW: Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 6(2), E26 (2008)
   Google Scholar
• Sleeper M, Fornasari B, Ellinwood NM et al.: Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII. Circulation 110, 815–820 (2004)
   Google Scholar
• Cachón-González MB, Wang SZ, Lynch L et al.: Effective gene therapy in an authentic model of Tay–Sachs-related diseases. Proc. Natl Acad. Sci. USA 103(27), 10373–10378 (2006)
   Google Scholar
• Passini MA, Bu J, Fidler JA et al.: Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann–Pick mouse. Proc. Natl Acad. Sci. USA 104(22), 9505–9510 (2007)
   Google Scholar
• Raper SE, Chirmule N, Lee FS et al.: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer Mol. Genet. Metab. 80(1–2), 148–158 (2003)
   Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 302(5644), 415–419 (2003)
   Google Scholar
• Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Maruyama K: Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.10.034 (2007) (Epub ahead of print).
   Google Scholar